Business context and reporting period
Werewolf Therapeutics, Inc. filed this Form 10-K for the fiscal year ended December 31, 2022. The company is a clinical-stage biotechnology developer of conditionally activated cancer immunotherapies using its PREDATOR platform. It had no approved products and no product-sale revenue. WTX-124 (IL-2) was in a Phase 1/1b trial; WTX-330 (IL-12) had FDA IND clearance in 2022, with first patient dosing reported in February 2023. The company also nominated WTX-712 (IL-21) as a development candidate. JZP898 (formerly WTX-613) is licensed globally to Jazz Pharmaceuticals.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Collaboration revenue | $16.4 million | None |
| Research and development expense | $53.8 million | $35.3 million |
| General and administrative expense | $18.7 million | $14.8 million |
| Operating loss | $56.1 million | $50.1 million |
| Net loss | $53.8 million | $50.0 million |
| Net cash used in operating activities | $40.6 million | $42.9 million |
| Cash and cash equivalents at year-end | $129.3 million | $157.5 million |
FY 2022 collaboration revenue comprised $7.3 million recognized from Jazz’s $15.0 million upfront payment and $9.1 million for reimbursable research services. No Jazz milestone or royalty payments had been received by year-end. Deferred revenue was $7.7 million. The company reported an accumulated deficit of $306.7 million. Product margins are not meaningful because it has no product sales.
R&D expense rose $18.5 million, mainly from manufacturing costs (+$8.8 million), personnel (+$5.2 million) and CRO costs (+$2.5 million). G&A increased $3.9 million, primarily from personnel and insurance. Net loss increased $3.8 million; the 2021 loss attributable to common stockholders was $201.9 million, including $151.9 million of preferred-stock accretion, versus $53.8 million in 2022.
At December 31, 2022, total current assets were $140.2 million and current liabilities were $24.0 million. The company had no term-loan borrowings outstanding at year-end. It borrowed $40.0 million from Pacific Western Bank on March 15, 2023; the loan bears a floating rate of at least 4.5%, has interest-only payments until amortization begins, and is secured by personal property other than intellectual property. The company also reported approximately $8.8 million in gross ATM proceeds from share sales between January 1 and March 23, 2023.
Material changes, outlook and key risks
- Management estimated that year-end cash and cash equivalents, together with anticipated collaboration revenue, would fund operating expenses and capital requirements through at least the fourth quarter of 2024. It cautioned that this estimate depends on assumptions; existing resources are not expected to fund complete development of the candidates.
- Management expects research and development spending and losses to continue increasing as clinical programs advance. It provided no product-revenue or profitability guidance.
- Management anticipated interim safety, tolerability and preliminary efficacy data from WTX-124 monotherapy cohorts in the fourth quarter of 2023. WTX-330’s Phase 1 trial was open for enrollment as of the filing discussion.
- The PWB loan agreement requires at least $50.0 million of gross proceeds from equity issuance, strategic partnerships or a similar transaction by September 30, 2023, and at least $20.0 million of unrestricted cash in PWB accounts after receipt of those proceeds. It also contains restrictive covenants and default provisions. Verify compliance and the effect of subsequent financing.
- Key risks include early-stage clinical uncertainty and possible adverse effects; complex biologics manufacturing and dependence on third-party manufacturers and CROs; competition; reliance on Jazz for JZP898 development; and the need for additional funding, which could dilute shareholders or require rights concessions.
- The company reported no material legal proceedings. It disclosed a related-party sublease with Crossbow Therapeutics, an entity affiliated with MPM Capital; approximately $0.8 million of sublease cash was received in 2022. Management reported effective disclosure controls and internal control over financial reporting at year-end, and said prior material weaknesses had been remediated.
Important facts for investors to verify
- Progress, enrollment, safety findings and timing of WTX-124 and WTX-330 clinical data, including whether the stated WTX-124 data timing was achieved.
- Cash burn, collaboration reimbursements and the assumptions underlying the stated runway through Q4 2024.
- Use and repayment terms of the $40.0 million PWB borrowing, floating interest costs, covenant compliance and the required capital-raising proceeds.
- Shares issued through the ATM after year-end and the resulting dilution; the filing reported 35,279,820 common shares outstanding as of March 17, 2023.
- Jazz’s development of JZP898, any milestone or royalty receipts, and the conditions attached to the potential milestone payments.